A Multicenter, Open-label, Phase Ii Study of Dasatinib in Combination With Melphalan and Prednisone (D-MP) in Advanced, Relapsed / Refractory Multiple Myeloma Patients.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2011
At a glance
- Drugs Dasatinib; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 06 May 2010 New trial record